Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Outdoor temperature inversely tied to cardio-cerebrovascular event morbidity

31 May 2020

The association between outdoor temperature and cardio-cerebrovascular events risk is mediated by temperature-driven blood pressure (BP), according to a study.

An increase of 6.7 mm Hg in systolic BP and 2.1 mm Hg in diastolic BP was observed for each 10 °C decrease in outdoor temperature when outdoor temperature was higher than 5 °C. Outdoor temperature was inversely associated with cardio-cerebrovascular event morbidity. Of note, central heating attenuated the increases in BP and cardio-cerebrovascular event morbidity.

“Indoor heating in winter is probably beneficial to cardio-cerebrovascular disease prevention by inhibition of BP increase,” the authors said.

Additionally, hypertension was associated with higher risks of cardio-cerebrovascular disease (hazard ratio [HR], 1.347, 95 percent confidence interval [CI], 1.281–1.415), cardiovascular disease (HR, 1.347, 95 percent CI, 1.282–1.416), major adverse cardiovascular events (HR, 1.670, 95 percent CI, 1.560–1.788), and stroke (HR, 1.683, 95 percent CI, 1.571–1.803).

In mediation analysis, BP potentially facilitated the association between outdoor temperature and cardio-cerebrovascular events risk.

In this study, the authors analysed the data of 38,589 participants in Harbin from the China Kadoorie Biobank during 2004–2008, with an average follow-up of 7.14 years. They performed linear regression analysis to estimate the association between outdoor temperature and BP. Cox regression and logistic regression analyses were conducted to assess the relationship of BP with cardio-cerebrovascular event risk. Finally, the authors carried out mediation analysis to explore the role of BP in the link between outdoor temperature and cardio-cerebrovascular risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.